公开(公告)号：US20160237072A1

公开(公告)日：2016-08-18

申请号：US15026759

申请日：2014-10-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew P. Degnan ,  Darrell Maxwell ,  Matthew D. Hill ,  Haiquan Fang ,  Michael F. Parker ,  Fukang Yang ,  Joanne J. Bronson ,  John E. Macor

IPC: C07D413/04 ,  C07D263/24 ,  C07D413/14

CPC classification number: C07D413/04 ,  C07B2200/07 ,  C07D263/24 ,  C07D413/14

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是mGluR5受体的配体，激动剂和部分激动剂，并且可用于治疗中枢神经系统的各种疾病。

公开(公告)号：US08846023B2

公开(公告)日：2014-09-30

申请号：US14021686

申请日：2013-09-09

Applicant: Bristol-Myers Squibb Company

Inventor： Carol Bachand ,  Makonen Belema ,  Daniel H. Deon ,  Andrew C. Good ,  Jason Goodrich ,  Clint A. James ,  Rico Lavoie ,  Omar D. Lopez ,  Alain Martel ,  Nicholas A. Meanwell ,  Van N. Nguyen ,  Jeffrey Lee Romine ,  Edward H. Ruediger ,  Lawrence B. Snyder ,  Denis R. St. Laurent ,  Fukang Yang ,  David R. Langley ,  Gan Wang ,  Lawrence G. Hamann

IPC: C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/13 ,  A61K31/7105 ,  A61K31/4745 ,  A61K31/7056 ,  A61K38/20 ,  A61K38/21 ,  C07D401/14

CPC classification number: A61K31/506 ,  A61K31/13 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4745 ,  A61K31/7056 ,  A61K31/7105 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/208 ,  A61K38/21 ,  A61K38/212 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

公开(公告)号：US20160311778A1

公开(公告)日：2016-10-27

申请号：US15194980

申请日：2016-06-28

Applicant: Bristol-Myers Squibb Company

Inventor： Carol Bachand ,  Makonen Belema ,  Daniel H. Deon ,  Andrew C. Good ,  Jason Goodrich ,  Clint A. James ,  Rico Lavoie ,  Omar D. Lopez ,  Alain Martel ,  Nicholas A. Meanwell ,  Van N. Nguyen ,  Jeffrey Lee Romine ,  Edward H. Ruediger ,  Lawrence B. Snyder ,  Denis R. St. Laurent ,  Fukang Yang ,  David R. Langley ,  Gan Wang ,  Lawrence G. Hamann

IPC: C07D233/64 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D403/14 ,  C07D401/14

CPC classification number: C07D233/64 ,  A61K31/4178 ,  A61K45/06 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07F5/025 ,  C07F7/0812

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

公开(公告)号：US09018390B2

公开(公告)日：2015-04-28

申请号：US13919027

申请日：2013-06-17

Applicant: Bristol-Myers Squibb Company

Inventor： Carol Bachand ,  Makonen Belema ,  Daniel H. Deon ,  Andrew C. Good ,  Jason Goodrich ,  Clint A. James ,  Rico Lavoie ,  Omar D. Lopez ,  Alain Martel ,  Nicholas A. Meanwell ,  Van N. Nguyen ,  Jeffrey Lee Romine ,  Edward H. Ruediger ,  Lawrence B. Snyder ,  Denis R. St. Laurent ,  Fukang Yang ,  David R. Langley ,  Lawrence G. Hamann

IPC: C07D233/00 ,  C07D233/02 ,  A01N43/50 ,  A61K31/415 ,  C07D403/14 ,  A61K31/4178 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07F7/10

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07F7/10

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。

公开(公告)号：US20150011754A1

公开(公告)日：2015-01-08

申请号：US14488990

申请日：2014-09-17

Applicant: Bristol-Myers Squibb Company

Inventor： Carol Bachand ,  Makonen Belema ,  Daniel H. Deon ,  Andrew C. Good ,  Jason Goodrich ,  Clint A. James ,  Rico Lavoie ,  Omar D. Lopez ,  Alain Martel ,  Nicholas A. Meanwell ,  Van N. Nguyen ,  Jeffrey Lee Romine ,  Edward H. Ruediger ,  Lawrence B. Snyder ,  Denis R. St. Laurent ,  Fukang Yang ,  David R. Langley ,  Lawrence G. Hamann

IPC: C07D413/14 ,  C07D401/14 ,  C07D233/64 ,  C07D403/14 ,  C07D405/14

CPC classification number: C07D233/64 ,  A61K31/4178 ,  A61K45/06 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07F5/025 ,  C07F7/0812

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

公开(公告)号：US20140017195A1

公开(公告)日：2014-01-16

申请号：US14021686

申请日：2013-09-09

Applicant: Bristol-Myers Squibb Company

Inventor： Carol Bachand ,  Makonen Belema ,  Daniel H. Deon ,  Andrew C. Good ,  Jason Goodrich ,  Clint A. James ,  Rico Lavole ,  Omar D. Lopez ,  Alain Martel ,  Nicolas A. Meanwell ,  Van N. Nguyen ,  Jeffrey Lee Romine ,  Edward H. Ruediger ,  Lawrence B. Snyder ,  Denis R. St. Laurent ,  Fukang Yang ,  David R. Langley ,  Gan Wang ,  Lawrence G. Hamann

IPC: A61K31/506 ,  A61K31/4178 ,  C07D417/14 ,  A61K31/427 ,  A61K31/13 ,  A61K38/20 ,  A61K38/21 ,  A61K31/7105 ,  A61K31/4745 ,  A61K31/7056 ,  C07D403/14 ,  C07D405/14

CPC classification number: A61K31/506 ,  A61K31/13 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4745 ,  A61K31/7056 ,  A61K31/7105 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/208 ,  A61K38/21 ,  A61K38/212 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.